Renalytix AI plc (RNLX)

Etorro trading 970x250
Renalytix AI plc (RNLX) Logo

About Renalytix AI plc

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom. Address: Avon House, Cardiff, United Kingdom, CF64 2EZ

Renalytix AI plc News and around…

Latest news about Renalytix AI plc (RNLX) common stock and company :

12 Health Care Stocks Moving In Tuesday's After-Market Session
17 May, 2022 FinancialContent

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 19.6% to $0.23 during Tuesday's after-market session. This security traded at a ...

AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors
12 May, 2022 Yahoo! Finance

PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the “Board”). On May 11, 2022, the Board appointe

Stocks That Hit 52-Week Lows On Wednesday
04 May, 2022 FinancialContent

During Wednesday's trading, 435 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: The ...

12 Health Care Stocks Moving In Thursday's After-Market Session
14 Apr, 2022 FinancialContent

Gainers Kaleido Biosciences (NASDAQ:KLDO) stock increased by 10.3% to $0.32 during Thursday's after-market session. Today's trading ...

Renalytix plc successful completion of $30.0 million financing package
08 Apr, 2022 Yahoo! Finance

Director/PDMR DealingNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is pleased to announce the successful completion of (i) an $8.8 million equity subscr

Renalytix plc Issue of shares
08 Apr, 2022 Yahoo! Finance

NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") have been issued to settle the purchase of 11,407 American Depositary Shares, each representing two Ordinary Shares, by employees who participated in the ESPP. This was carried out at a subscription price of $7.8795 per

12 Health Care Stocks Moving In Monday's Intraday Session
04 Apr, 2022 FinancialContent

Gainers Cognition Therapeutics (NASDAQ:CGTX) shares increased by 26.2% to $3.28 during Monday's regular session. ...

Renalytix: Q2 Earnings Insights
31 Mar, 2022 FinancialContent

Renalytix (NASDAQ:RNLX) reported its Q2 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
31 Mar, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, trader! We're getting ready for another busy day of trading with the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Renalytix announces a $30.0 million financing package
31 Mar, 2022 Yahoo! Finance

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH SUC

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
31 Mar, 2022 Yahoo! Finance

LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended December 31, 2021. Recent Highlights Quarter over quarter growth in KidneyIntelX testing volumeQuarter over quarter growth in active physicians orderin

23 Stocks Moving in Thursday's Pre-Market Session
31 Mar, 2022 FinancialContent

Gainers IZEA Worldwide, Inc. (NASDAQ: IZEA) rose 33.3% to $1.92 in pre-market trading after the company reported Q4 EPS results ...

Earnings Scheduled For March 31, 2022
31 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth ...

Earnings Preview For Renalytix AI
30 Mar, 2022 FinancialContent

Renalytix AI (NASDAQ:RNLX) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to ...

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
30 Mar, 2022 Yahoo! Finance

NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced that, following the Company’s announcement on February 22, 2022, Timothy Scannell has been appointed to the Board as an independent Non-Executive Director of Renalytix. As an accomplished leader in healthcare innovation, Mr. Scannell brings more than 30 years of experience in medical technology to the Renalytix Board, and previously served as President and C.O.O. of Stryker. M

Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
29 Mar, 2022 Yahoo! Finance

KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched electronic health records from multiple centers across the U.S.NEW YORK and SALT LAKE CITY, March 29, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the proprietary Renalytix Accelerating Precision medicine In Diabetes (RAPID) biorepository is on track to exceed 4,000 unique patient biospecimens with matching, deidentified electronic health record data in 202

Relative Strength Alert For Renalytix
28 Mar, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31
25 Mar, 2022 Yahoo! Finance

NEW YORK and SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release its second quarter and first half fiscal year 2022 financial results on Thursday, March 31, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (

Stocks That Hit 52-Week Lows On Tuesday
15 Mar, 2022 FinancialContent

During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week ...

Renalytix Launches National Physician Access To KidneyIntelX Platform
09 Mar, 2022 FinancialContent

Renalytix plc(NASDAQ: RNLX) has launched its new provider access portal, myIntelX, toprovide nationwide online access for ...

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute
09 Mar, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech ...

Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
09 Mar, 2022 Yahoo! Finance

myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all Renalytix healthcare provider partnersNEW YORK and SALT LAKE CITY, March 09, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the launch of its new provider access portal, myIntelX, which will provide nationwide online access for physicians to order KidneyIntelX bioprognostic™ testing for more accurate identification of patients at

KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care
24 Feb, 2022 Yahoo! Finance

Data highlights strength of KidneyIntelX for clinical use in early-stage diabetic kidney disease patients beyond commonly used markers UACR and historical eGFR change over timeNEW YORK and SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the presentation of new clinical data for KidneyIntelX™ bioprognostic™ testing at the World Congress of Nephrology Annual Meeting. The results provide robust prognostic information demonstrating the value

Renalytix to Present at Cowen 42nd Annual Health Care Conference
22 Feb, 2022 Yahoo! Finance

NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42nd Annual Health Care Conference. Renalytix’s management is scheduled to participate in a fireside chat on Wednesday, March 9, 2022, at 10:30 a.m. EST. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at inv

Renalytix to Appoint Timothy Scannell to Board of Directors
22 Feb, 2022 Yahoo! Finance

NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director. Mr. Scannell is a distinguished leader in healthcare innovation, who brings more than 30 years of experience from his time at Stryker, one of the world’s leading medical technology companies. During his time as President and C.O.O., Mr. Scannell was responsible for all

Stocks That Hit 52-Week Lows On Friday
18 Feb, 2022 FinancialContent

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The ...

Stocks That Hit 52-Week Lows On Monday
07 Feb, 2022 FinancialContent

On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in ...

Renalytix Becomes Oversold (RNLX)
07 Feb, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
27 Jan, 2022 Yahoo! Finance

NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Renalytix’s management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available f

Renalytix AI PLC Sponsored ADR (RNLX) Surges 10.4%: Is This an Indication of Further Gains?
20 Jan, 2022 Yahoo! Finance

Renalytix AI PLC Sponsored ADR (RNLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Renalytix AI plc (RNLX) is a NASDAQ Common Stock listed in , ,

970x250